

D.R.U.G. 

**UZ**

Universitair Ziekenhuis Gent


  
UNIVERSITEIT  
GENT

# A PILOT, PHASE IB FEASIBILITY STUDY OF ARGX-110 IN PATIENTS WITH NASOPHARYNGEAL CARCINOMA (NPC).

Prof. Dr. Sylvie Rottey – XX May 2017

# NPC- Definition

Nasopharyngeal carcinoma (NPC) is a cancer that occurs in the nasopharynx, which is located behind the nose and above the back of the throat.



# NPC - Epidemiology

- 0.5 – 2 new cases/100 000 people (Europe + VS)
- male > female
- linked with Epstein Barr Virus ( EBV) - **% pos?**

# NPC - Treatment

Highly radiosensitive

Highly chemosensitive


=> platinum based chemoRT = golden standard  
(stage III/IV)


=> platinum based chemotherapy is = golden  
standard for metastatic disease

# NPC - Outcome


For **metastatic NPC**, median survival is only 12–20 months  
=> Need for new therapies (e.g. targeted agents)

# Adaptive Immune response










ARGX-110: monoclonal anti-CD70 antibody **op de vorige slide in de tekening bij te zetten ipv deze slide ?**

## anti-CD70 mAb

  
↓ number of T regs

  
direct cytotoxic effect



# Results

- n= eleven patients (nine male, two female) were enrolled in our center since February 2015.
- median age of 47 years (range 23-76)
- All patients were diagnosed with stage III (n=2) or stage IV (n=9) NPC.

## Results

- median number of cycles administered was three (range 1 to 18).
- Administration of ARGX-110 was well tolerated. One patient was hospitalized because of infection for which treatment was delayed for three weeks. Two other patients developed an infusion reaction (grade 1-2).

## Conclusion

- administration of ARGX-110, 5mg/kg IV every three weeks, is feasible in patients with NPC. Results on PFS and OS overall survival will be reported after completion of the trial.
- the exploration of predictive biomarkers is ongoing **(kun je er enkele oplisten?)**

Prof. Dr. Sylvie Rottey

M.D.; PhD

HEYMANS INSTITUTE OF PHARMACOLOGY  
DEPARTMENT OF MEDICAL ONCOLOGY  
DRUG RESEARCH UNIT GENT

 Ghent University

 @ugent

 Ghent University

E sylvie.rottey@ugent.be

T +32 9 332 00 00

[www.ugent.be](http://www.ugent.be)